QIAGEN Pre-Tax Profit Margin 2010-2023 | QGEN

Current and historical pre-tax profit margin for QIAGEN (QGEN) from 2010 to 2023. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue. QIAGEN pre-tax profit margin for the three months ending March 31, 2023 was .
QIAGEN Pre-Tax Profit Margin Historical Data
Date TTM Revenue TTM Pre-Tax Income Pre-Tax Margin
2023-03-31 $2.00B $0.43B 21.36%
2022-12-31 $2.14B $0.51B 24.00%
2022-09-30 $2.23B $0.57B 25.74%
2022-06-30 $2.26B $0.63B 27.78%
2022-03-31 $2.31B $0.66B 28.63%
2021-12-31 $2.25B $0.63B 27.77%
2021-09-30 $2.24B $0.72B 31.96%
2021-06-30 $2.19B $0.59B 27.09%
2021-03-31 $2.07B $0.55B 26.73%
2020-12-31 $1.87B $0.44B 23.48%
2020-09-30 $1.71B $0.25B 14.72%
2020-06-30 $1.61B $-0.00B -0.19%
2020-03-31 $1.55B $-0.06B -3.87%
2019-12-31 $1.53B $-0.08B -5.11%
2019-09-30 $1.52B $-0.08B -5.21%
2019-06-30 $1.51B $0.22B 14.55%
2019-03-31 $1.51B $0.21B 14.20%
2018-12-31 $1.50B $0.23B 14.98%
2018-09-30 $1.50B $0.19B 12.77%
2018-06-30 $1.48B $0.17B 11.54%
2018-03-31 $1.45B $0.14B 9.42%
2017-12-31 $1.42B $0.11B 8.04%
2017-09-30 $1.39B $0.07B 4.76%
2017-06-30 $1.36B $0.05B 3.82%
2017-03-31 $1.35B $0.06B 4.67%
2016-12-31 $1.34B $0.06B 4.26%
2016-09-30 $1.32B $0.12B 9.17%
2016-06-30 $1.30B $0.12B 9.34%
2016-03-31 $1.28B $0.13B 9.91%
2015-12-31 $1.28B $0.14B 10.62%
2015-09-30 $1.29B $0.10B 7.82%
2015-06-30 $1.31B $0.10B 7.62%
2015-03-31 $1.33B $0.11B 8.30%
2014-12-31 $1.34B $0.12B 8.85%
2014-09-30 $1.35B $0.14B 10.04%
2014-06-30 $1.33B $0.13B 9.62%
2014-03-31 $1.32B $0.04B 3.19%
2013-12-31 $1.30B $0.04B 2.84%
2013-09-30 $1.29B $0.05B 3.49%
2013-06-30 $1.27B $0.05B 3.86%
2013-03-31 $1.26B $0.14B 10.70%
2012-12-31 $1.25B $0.15B 11.56%
2012-09-30 $1.24B $0.08B 6.77%
2012-06-30 $1.23B $0.09B 7.59%
2012-03-31 $1.20B $0.09B 7.83%
2011-12-31 $1.17B $0.10B 8.21%
2011-09-30 $1.12B $0.16B 14.54%
2011-06-30 $1.11B $0.17B 15.10%
2011-03-31 $1.09B $0.17B 15.36%
2010-12-31 $1.09B $0.17B 15.92%
2010-09-30 $1.09B $0.18B 16.24%
2010-06-30 $1.08B $0.18B 16.64%
2010-03-31 $1.05B $0.18B 17.09%
2009-12-31 $1.01B $0.17B 17.03%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $10.347B $2.142B
QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed a comprehensive portfolio of proprietary, consumable products, and automated solutions for sample collection. Qiagen has subsidiaries several other countries with good sales potential. Segment Details Consumables: These are typically sample preparation or test kits that contain all the necessary reagents and buffers, and a manual including protocols and relevant background information. Automated Instruments: These automate the use of Sample & Assay Technologies into efficient solutions for a broad range of laboratory needs. Customer Classes: QIAGEN focuses on 4 principal segments or customer classes for sample and assay technologies:? Molecular Diagnostics, Applied Testing, Pharma and Academia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $137.206B 8.38
GSK (GSK) United Kingdom $71.088B 9.92
Bio-Rad Laboratories (BIO.B) United States $10.988B 29.38
Ginkgo Bioworks Holdings (DNA) United States $3.670B 0.00
Arcus Biosciences (RCUS) United States $1.582B 0.00
Biohaven (BHVN) United States $1.578B 0.00
Emergent Biosolutions (EBS) United States $0.423B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.192B 0.00
Enzo Biochem (ENZ) United States $0.109B 0.00
SQZ Biotechnologies (SQZ) United States $0.016B 0.00